Castle Biosciences

The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.

The GenomeWeb index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The GenomeWeb Index, which now has 32 companies, lost 2.6 percent in September while the Dow Jones Industrial Average gained 2 percent over the same period.

The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractor Palmetto for the week of 8/22/2019.

Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.

The company markets two tests for skin cancer, including DecisionDx-Melanoma for identifying high-risk Stage I and II cutaneous melanoma patients.

The company markets genetic tests for skin cancer including DecisionDx-Melanoma for identifying high-risk stage I and II cutaneous melanoma patients.